These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

497 related articles for article (PubMed ID: 26900075)

  • 41. Glioblastoma precision therapy: From the bench to the clinic.
    Zhou Y; Wu W; Bi H; Yang D; Zhang C
    Cancer Lett; 2020 Apr; 475():79-91. PubMed ID: 32004571
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Targeting Protein Kinases for the Treatment of Glioblastoma Multiforme: Linking Basic Studies to Clinical Applications.
    Zhou A
    Curr Pharm Des; 2017 Nov; 23(29):4290-4302. PubMed ID: 28699529
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status.
    Brandes AA; Franceschi E; Tosoni A; Benevento F; Scopece L; Mazzocchi V; Bacci A; Agati R; Calbucci F; Ermani M
    Cancer; 2009 Aug; 115(15):3512-8. PubMed ID: 19514084
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Molecular Mechanisms of Treatment Resistance in Glioblastoma.
    Ou A; Yung WKA; Majd N
    Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33396284
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Encapsulation of temozolomide in a tumor-targeting nanocomplex enhances anti-cancer efficacy and reduces toxicity in a mouse model of glioblastoma.
    Kim SS; Rait A; Kim E; DeMarco J; Pirollo KF; Chang EH
    Cancer Lett; 2015 Dec; 369(1):250-8. PubMed ID: 26325605
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effective treatment of glioblastoma requires crossing the blood-brain barrier and targeting tumors including cancer stem cells: The promise of nanomedicine.
    Kim SS; Harford JB; Pirollo KF; Chang EH
    Biochem Biophys Res Commun; 2015 Dec; 468(3):485-9. PubMed ID: 26116770
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Molecular, histopathological, and genomic variants of glioblastoma.
    Karsy M; Huang T; Kleinman G; Karpel-Massler G
    Front Biosci (Landmark Ed); 2014 Jun; 19(7):1065-87. PubMed ID: 24896337
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comprehensive analysis of glycolytic enzymes as therapeutic targets in the treatment of glioblastoma.
    Sanzey M; Abdul Rahim SA; Oudin A; Dirkse A; Kaoma T; Vallar L; Herold-Mende C; Bjerkvig R; Golebiewska A; Niclou SP
    PLoS One; 2015; 10(5):e0123544. PubMed ID: 25932951
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Topics in chemotherapy, molecular-targeted therapy, and immunotherapy for newly-diagnosed glioblastoma multiforme.
    Okonogi N; Shirai K; Oike T; Murata K; Noda SE; Suzuki Y; Nakano T
    Anticancer Res; 2015 Mar; 35(3):1229-35. PubMed ID: 25750269
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Recognizing and correcting failures in glioblastoma treatment.
    Shah AH; Graham R; Bregy A; Thambuswamy M; Komotar RJ
    Cancer Invest; 2014 Jul; 32(6):299-302. PubMed ID: 24766304
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Immune check-point in glioblastoma multiforme.
    De Felice F; Pranno N; Marampon F; Musio D; Salducci M; Polimeni A; Tombolini V
    Crit Rev Oncol Hematol; 2019 Jun; 138():60-69. PubMed ID: 31092387
    [TBL] [Abstract][Full Text] [Related]  

  • 52. An Update on Glioblastoma Biology, Genetics, and Current Therapies: Novel Inhibitors of the G Protein-Coupled Receptor CCR5.
    Lah Turnšek T; Jiao X; Novak M; Jammula S; Cicero G; Ashton AW; Joyce D; Pestell RG
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33923334
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Molecular targeted therapy in recurrent glioblastoma: current challenges and future directions.
    Patel M; Vogelbaum MA; Barnett GH; Jalali R; Ahluwalia MS
    Expert Opin Investig Drugs; 2012 Sep; 21(9):1247-66. PubMed ID: 22731981
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Single cell-derived clonal analysis of human glioblastoma links functional and genomic heterogeneity.
    Meyer M; Reimand J; Lan X; Head R; Zhu X; Kushida M; Bayani J; Pressey JC; Lionel AC; Clarke ID; Cusimano M; Squire JA; Scherer SW; Bernstein M; Woodin MA; Bader GD; Dirks PB
    Proc Natl Acad Sci U S A; 2015 Jan; 112(3):851-6. PubMed ID: 25561528
    [TBL] [Abstract][Full Text] [Related]  

  • 55. miR-144-3p exerts anti-tumor effects in glioblastoma by targeting c-Met.
    Lan F; Yu H; Hu M; Xia T; Yue X
    J Neurochem; 2015 Oct; 135(2):274-86. PubMed ID: 26250785
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Targeting Autophagy in Glioblastoma.
    Noonan J; Zarrer J; Murphy BM
    Crit Rev Oncog; 2016; 21(3-4):241-252. PubMed ID: 27915974
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Harnessing nanomedicine for therapeutic intervention in glioblastoma.
    Gutkin A; Cohen ZR; Peer D
    Expert Opin Drug Deliv; 2016 Nov; 13(11):1573-1582. PubMed ID: 27292970
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Drug delivery challenges and future of chemotherapeutic nanomedicine for glioblastoma treatment.
    Ganipineni LP; Danhier F; Préat V
    J Control Release; 2018 Jul; 281():42-57. PubMed ID: 29753958
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The role of glioma stem cells in chemotherapy resistance and glioblastoma multiforme recurrence.
    Auffinger B; Spencer D; Pytel P; Ahmed AU; Lesniak MS
    Expert Rev Neurother; 2015; 15(7):741-52. PubMed ID: 26027432
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Should biomarkers be used to design personalized medicine for the treatment of glioblastoma?
    Weller M; Wick W; Hegi ME; Stupp R; Tabatabai G
    Future Oncol; 2010 Sep; 6(9):1407-14. PubMed ID: 20919826
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.